BRIEF published on 12/05/2025 at 18:39, 9 months 17 days ago Valneva Updates Share and Voting Rights as of November 2025 Stock Options Euronext Paris Voting Rights Valneva Double Voting Rights
BRIEF published on 12/05/2025 at 18:39, 9 months 17 days ago Valneva met à jour ses actions et ses droits de vote à compter de novembre 2025 Euronext Paris Options D'achat D'actions Droit De Vote Valneva Double Droit De Vote
PRESS RELEASE published on 12/05/2025 at 18:34, 9 months 17 days ago VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025 VALNEVA déclare des actions et des droits de vote, dont un passage en droit de vote double et un exercice d'options de souscription d'actions. Informations sur le siège social et le marché réglementé Euronext Paris Déclaration Droits De Vote Actions Valneva
PRESS RELEASE published on 12/05/2025 at 18:34, 9 months 17 days ago VALNEVA Declaration of shares and voting rights: November 30, 2025 VALNEVA declares changes in shares and voting rights, including double voting rights granted on ordinary shares and transfer into bearer form Euronext Paris Voting Rights Shares Valneva Double Voting Rights
BRIEF published on 12/03/2025 at 11:03, 9 months 20 days ago Valneva SE: Promising Developments in Lyme Disease Vaccine Valneva SE Lyme Disease Vaccine Market Forecast Pfizer VLA15
BRIEF published on 12/03/2025 at 11:03, 9 months 20 days ago Valneva SE : Développements prometteurs dans le domaine du vaccin contre la maladie de Lyme Valneva SE Vaccin Contre La Maladie De Lyme Prévisions Du Marché Pfizer VLA15
PRESS RELEASE published on 12/03/2025 at 10:58, 9 months 20 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation for Valneva SE, raising target price to €6.80. VLA15 vaccine progress and market potential analyzed Buy Recommendation Research Update Valneva SE Market Potential VLA15 Vaccine
BRIEF published on 11/04/2025 at 07:05, 10 months 19 days ago Valneva's Phase 1 Trial Yields Positive Results for Zika Vaccine Phase 1 Trial Valneva Immunogenicity Zika Vaccine Adjuvant
BRIEF published on 11/04/2025 at 07:05, 10 months 19 days ago L'essai de phase 1 de Valneva donne des résultats positifs pour le vaccin contre le Zika Valneva Immunogénicité Essai De Phase 1 Adjuvant Vaccin Contre Le Zika
PRESS RELEASE published on 11/04/2025 at 07:00, 10 months 19 days ago Valneva annonce des résultats positifs de Phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika Valneva annonce des résultats positifs de phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika, montrant une réponse immunitaire améliorée Valneva Immunitaire Phase 1 Vaccin Zika
Published on 09/23/2026 at 13:30, 35 minutes ago Engineering Cost Study Validates Commercial-Scale U.S. HPMSM Capital Cost and Establishes EMM Capital Cost for Electric Metals' North Star Manganese Project
Published on 09/23/2026 at 13:30, 35 minutes ago Green Bridge Metals Corporation Announces Phase 2 Diamond Drill Program at the Titac Titanium-Copper-Vanadium Project, Minnesota, USA
Published on 09/23/2026 at 13:00, 1 hour 5 minutes ago Abasca Announces Filing of Technical Report Regarding Positive Preliminary Economic Assessment for the Loki Flake Graphite Deposit and Private Placement of $2.25 Million
Published on 09/23/2026 at 13:00, 1 hour 5 minutes ago New Mineralised VMS System Discovered at Storm's Gold Standard Project
Published on 09/23/2026 at 12:40, 1 hour 25 minutes ago SouthGobi Announces Update on Upcoming Special Meeting of Shareholders and Postponement of The Record Date
Published on 09/23/2026 at 13:54, 10 minutes ago Turkiye Garanti Bankasi A.S.: Announcement Regarding the Investigation by the Competition Board
Published on 09/23/2026 at 13:51, 14 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program XS3183304503
Published on 09/23/2026 at 13:48, 17 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program XS3183304412
Published on 09/23/2026 at 13:45, 20 minutes ago Turkiye Garanti Bankasi A.S.: Prospectus – Issuer Information Document
Published on 09/23/2026 at 13:40, 24 minutes ago Turkiye Garanti Bankasi A.S.: Prospectus – Capital Markets Instrument Note
Published on 09/23/2026 at 08:00, 6 hours 5 minutes ago Résultats semestriels 2026 - ANR par action : 101,90 €, en progression de 8,18 % - Capitaux propres consolidés : 774,5 M€
Published on 09/22/2026 at 18:00, 20 hours 5 minutes ago Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 18:00, 20 hours 5 minutes ago Résultats consolidés du premier semestre 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 20 hours 20 minutes ago Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026
